Study of ST316 for familial adenomatous polyposis
Part of Cancer, Digestive system, Genetic & congenital clinical trials.
This study tests a new drug called ST316 to see if it can help people with familial adenomatous polyposis (FAP), a condition that causes many polyps in the colon. The goal is to reduce the number or size of these polyps to lower the risk of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of FAP through genetic testing and have at least six polyps that are 5 to 9 mm in size.
- You have had surgery to remove your colon (colectomy) at least 12 months before the study, and you have no ongoing complications from that surgery.
- You have polyps in your rectum or pouch at the start of the study, and any polyps larger than 10 mm have been removed during a colonoscopy before starting the drug.
- You agree to avoid certain supplements and medications (like turmeric, fish oil, oral steroids, and NSAIDs) during the study, unless you take low-dose aspirin for heart protection.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study, and you agree to use effective birth control if you could have children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called eRapa for people with Familial Adenomatous Polyposis (FAP), a condition that causes many polyps in the colon and raises the risk of cancer. The goal is to see if eRapa can help reduce polyps and improve outcomes.
This trial tests whether taking vitamin B1 can help people with familial adenomatous polyposis (FAP) reduce the number of polyps in their colon or rectum. It is designed for people who still have most of their bowel and have more than 10 polyps.
This study uses a tiny camera to look at the pouch created after FAP surgery. It aims to see how well the pouch is doing and if any polyps are growing there.
This trial provides early access to an experimental drug called eRapa (a low dose of rapamycin) for people with familial adenomatous polyposis (FAP). The drug may help slow or reduce polyp growth, possibly delaying or avoiding surgery.
This trial tests a new drug, TPST-1495, to reduce the number of benign polyps in the small intestine for people with a condition called familial adenomatous polyposis (FAP). If you join, you will likely not know if you receive the drug or a placebo, to see if the drug is helpful.
This early-phase trial studies REC-4881 in adults with familial adenomatous polyposis (FAP), a condition that causes many colon/rectum and duodenal polyps. It aims to see whether the treatment can safely help control or shrink polyp growth in people who have had bowel surgery.
Hear when a new Familial Adenomatous Polyposis (FAP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.